Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Fosamax Plus D To Be Priced On Par With Predecessor

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's Fosamax Plus D adds weekly dose of vitamin D to the once-weekly osteoporosis agent. Plus D will reach the market around the same time as Roche/GlaxoSmithKline's once-monthly Boniva.

You may also be interested in...



P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen

FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.

P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen

FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.

Roche/GSK Boniva Once-Monthly To Be Launched In April

The companies are planning "substantial" DTC ad campaigns, Roche says. FDA approves supplemental NDA for once-monthly ibandronate for treatment of osteoporosis in postmenopausal women. Boniva will be priced competitively to the currently marketed bisphosphonates, Roche says.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel